EGFR and neoplasm: FC-TPP11 also promotes the efficacy of co-administered doxorubicin, and its coupling to cetuximab (Erbitux), a monoclonal antibody against EGFR, significantly improves its tumor penetration and accumulation without compromising its serum half-life [388].